20:12 , May 8, 2017 |  BC Extra  |  Financial News

Aadi raises $23M series A round

Aadi Bioscience Inc. (Pacific Palisades, Calif.) raised $23 million in a series A led by Hermed Capital. Also participating were Celgene Corp. (NASDAQ:CELG), Vivo Capital, Decheng Capital, Helsinn Investment Fund and Star Summit Ventures. Aadi...
01:13 , May 16, 2015 |  BC Extra  |  Company News

Sorrento rises on NantWorks deal

Sorrento Therapeutics Inc. (NASDAQ:SRNE) gained $1.51 (13%) to $13.01 on news that its Igdrasol Inc. subsidiary will be acquired by Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.) for $90 million up front. The acquisition will...
01:56 , May 14, 2015 |  BC Extra  |  Financial News

NantBioscience raises $100M

NantBioscience Inc. raised $100 million in equity financing, according to an SEC NantWorks LLC , is developing a pipeline of targeted therapies based on nanoparticle albumin-bound (nab) technology. NantBioscience received $75 million up front in...
07:00 , Oct 13, 2014 |  BioCentury  |  Finance

Sovereign data

Now that investors have injected almost half a billion dollars into NantHealth, one question is whether the subsidiary of NantWorks LLC can ever reach a valuation that justifies its war chest. This month, NantHealth announced...
02:57 , Oct 2, 2014 |  BC Extra  |  Financial News

NantHealth completes $320M B round

NantHealth, a subsidiary of Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.), raised $250 million from the Kuwait Investment Authority (KIA) in the final close of its series B, bringing to $320 million the total raised...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Celgene, NantWorks deal

Celgene partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of Soon-Shiong's former company, Abraxis Bioscience Inc....
08:00 , Jan 20, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celltrion Inc. (KOSDAQ:068270) lost W350 to W45,650 last week after South Korea's Ministry of Food and Drug Safety (MFDS) approved Herzuma trastuzumab as a biosimilar of Herceptin trastuzumab to treat early and advanced...
02:03 , Jan 15, 2014 |  BC Extra  |  Company News

Celgene, NantBioscience in cancer deal

Celgene Corp. (NASDAQ:CELG) partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks LLC (Los Angeles, Calif.) to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Clinical News

Abraxane nab-paclitaxel regulatory update

FDA approved an sNDA from Celgene to expand the label of Abraxane nab-paclitaxel to include first-line treatment of advanced pancreatic cancer in combination with gemcitabine. The label includes a claim of overall survival (OS) benefit...
00:58 , Sep 7, 2013 |  BC Extra  |  Top Story

FDA approves Abraxane for pancreatic cancer

FDA approved an sNDA from Celgene Corp. (NASDAQ:CELG) to expand the label of Abraxane nab-paclitaxel to include first-line treatment of advanced pancreatic cancer in combination with gemcitabine. The label includes a claim of overall survival...